Todd Riehl

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 537 citations · Full text

Medicine, Oncology, Pharmacology +15

Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart et al. · JAMA Oncology · 2017 · 405 citations · Full text

Medicine, Oncology, Pharmacology +13

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Marcia S. Brose, Maria E. Cabanillas, Ezra E.W. Cohen et al. · The Lancet Oncology · 2016 · 384 citations · Full text

Medicine, Oncology, Pharmacotherapy +4